The use of Zostavax in Spain: the economic case for vaccination of individuals aged 50 years and older.

@article{LpezBelmonte2016TheUO,
  title={The use of Zostavax in Spain: the economic case for vaccination of individuals aged 50 years and older.},
  author={Juan Luis L{\'o}pez-Belmonte and Ram{\'o}n Cisterna and A. Gil de Miguel and Caroline Guilmet and Florence Bianic and Mathieu Uhart},
  journal={Journal of medical economics},
  year={2016},
  volume={19 6},
  pages={576-86}
}
Background Population aging brings up a number of health issues, one of which is an increased incidence of herpes zoster (HZ) and its complication, post-herpetic neuralgia (PHN). Zostavax vaccine has recently become available to prevent HZ and PHN. This study evaluates the cost-effectiveness of vaccination against HZ in Spain considering a vaccination of the population aged 50 years and older and comparing this to the current situation where no vaccination is being administered. Methods An… CONTINUE READING